The biphasic course of changes of left ventricular outflow gradient after alcohol septal ablation for hypertrophic obstructive cardiomyopathy;Dwufazowy charakter zmian gradientu w drodze odpływu lewej komory po alkoholowej ablacji kardiomiopathii przerostowej zawȩżaja̧ cej

Kardiologia Polska

Volumn 60, Issue 2, 2004, Pages 133-137

  Veselka, Josef ^a   Duchoňová, Radka ^a   Procházková, Sárka ^a   Homolová, Ingrid ^a   Palenickova, Jana ^a   Zemánek, David ^a   Pernišová, Zuzana ^a   Tesař, David ^a   Kornacewicz Jach, Zdzisława ^b  

^a UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^b POMERANIAN MEDICAL UNIVERSITY   (Poland)

Author keywords

Ablation; Alcohol; Gradient; Hypertrophic obstructive cardiomyopathy

Indexed keywords

ALCOHOL;

ADULT; AGED; ALCOHOL SEPTAL ABLATION; ARTICLE; CLINICAL ARTICLE; DOPPLER ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE OUTFLOW TRACT; HEART MUSCLE NECROSIS; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY; MALE; PERCUTANEOUS CORONARY INTERVENTION; STUNNED HEART MUSCLE; SURVIVAL RATE; SYMPTOMATOLOGY; TIME SERIES ANALYSIS;

EID: 1442277027     PISSN: 00229032     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Boekstegers P., Steinbigler P., Molnar A. et al.: Pressure-guided nonsurgical myocardial reduction induced by small septal infarctions in hypertrophic obstructive cardiomyopathy. J. Am. Coll. Cardiol. 2001, 38, 846-53.
2. Faber L., Seggewiss H., Kuhn H. et al.: Catheter interventional septal ablation for hypertrophic obstructive cardiomyopathy: an analysis of the follow-up data from the Registry of the German Society of Cardiology. J. Am. Coll. Cardiol. 2002, 39 (Suppl A), 3A.
3. Faber L., Welge D., Ziemssen P. et al.: Septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: an analysis of the patients with dissatisfactory intervention results. J. Am. Coll. Cardiol. 2003, 41 (Suppl A), 145A.
4. Lakkis N., Nagueh S., Killip D. et al.: Nonsurgical septal reduction for symptomatic hypertrophic obstructive cardiomyopathy: the Baylor experience. J. Interv. Cardiol. 2000, 13, 157-9.
5. Lawrenz T., Lieder F., Leuner C. et al.: Transcoronary ablation of septal hypertrophy for hypertrophic obstructive cardiomyopathy: studies of infarction markers and alcohol spill over. Eur. Heart J. 2003, 24 (Suppl), 556.
6. Maron B.J., McKenna W.J., Danielson G.K. et al.: American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. Eur. Heart J. 2003, 24, 1965-91.
7. Mazur W., Nagueh S.F., Lakkis N.M. et al.: Regression of left ventricular hypertrophy after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. Circulation 2001, 103, 1492-6.
8. Nagueh S., Lakkis N.M., Middleton K. et al.: Changes in left ventricular filling and left atrial function six months after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. J. Am. Coll. Cardiol. 1999, 34, 1123-8.
9. Nagueh S.F., Lakkis N.M., Middleton K.J. et al.: Changes in left ventricular diastolic function 6 months after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. Circulation 1999, 99, 344-7.
10. Rovner A., Sitges M., Smith R. et al.: Improvement in diastolic suction in patients with hypertrophic obstructive cardiomyopathy after septal ablation. J. Am. Coll. Cardiol. 2002, 39 (Suppl A), 451A.
11. Rużyłło W., Chojnowska L., Demkow M. et al.: Left ventricular outflow tract gradient decrease with non-surgical myocardial reduction improves exercise capacity in patients with hypertrophic obstructive cardiomyopathy. Eur. Heart J. 2000, 21, 770-7.
12. Seggewiss H., Faber L., Gleichmann U.: Percutaneous transluminal septal ablation in hypertrophic obstructive cardiomyopathy. Thorac. Cardiovasc. Surg. 1999, 47, 94-100.
13. Sigwart U.: Non-surgical myocardial reduction for patients with hypertrophic obstructive cardiomyopathy. Eur. Heart J. 2001, 3 (Suppl L), L38-L42.
14. Sigwart U.: Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet 1995, 346, 211-4.
15. Sitges M., Shiota T., Lever H.M. et al.: Comparison of left ventricular diastolic function in obstructive hypertrophic cardiomyopathy in patients undergoing percutaneous septal alcohol ablation versus surgical myotomy/myectomy. Am. J. Cardiol. 2003, 91, 817-21.
16. Veselka J., Honk T.: The management of hypertrophic obstructive cardiomyopathy: the role of percutaneous transluminal septal myocardial ablation. Cardiol. 2000, 9, 327-32.
17. Veselka J., Honk T.: Early remodeling of left ventricle and improvement of myocardial performance in patients after percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy. Int. J. Cardiol. 2003, 88, 27-32.
18. Flores-Ramirez R., Lakkis N.M., Middleton K.J. et al.: Echocardiographic insights into the mechanisms of relief of left ventricular outflow tract obstruction after nonsurgical septal reduction therapy in patients with hypertrophic obstructive cardiomyopathy. J. Am. Coll. Cardiol. 2001, 37, 208-14.